What drove the intraday drop in 9G2.SI stock on 24 Feb 2026?

The intraday drop was driven by weak liquidity and balance-sheet concerns. 9G2.SI stock fell **6.52%** to **S$0.043** amid below-average volume and negative margin metrics that raised short-term funding risk.

What is Meyka AI's forecast for 9G2.SI stock?

Meyka AI's forecast model projects **S$0.05** monthly, **S$0.09** quarterly and **S$0.10610** yearly. These are model-based projections and not guarantees for 9G2.SI stock.

How does valuation of 9G2.SI stock compare with the healthcare sector?

9G2.SI stock posts a negative PE of **-1.43** versus the healthcare sector average PE of **22.98**. The company also has a low current ratio of **0.27**, below the sector average of **4.51**.

Should I trade 9G2.SI stock during this intraday weakness?

Intraday trading may suit experienced traders only. Look for volume confirmation, RSI recovery above **40**, and clear news on capital or cash flow. 9G2.SI stock remains high risk.

SG Stocks

9G2.SI drops 6.52% to S$0.043 intraday on 24 Feb 2026: watch liquidity risks

ByHuzaifa Zahoor February 24, 2026

Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI stock) fell 6.52% intraday to S$0.043 on 24 Feb 2026 on the SES in Singapore. The move accelerated after an opening at S$0.046 and a session low of S$0.041 as volume reached 3,662,500 shares. Traders flagged weak liquidity and stretched balance-sheet ratios, while the stock trades below its 50-day average of S$0.060. This intraday decline keeps 9G2.SI stock among the top losers on the Singapore market and raises questions on near-term funding and margin recovery.